BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biogen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biogen's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06685757-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06685757)
DESCRIPTION:Felzartamab\, phase 3.\nStudy: A Study to Learn More About the 
 Effects and Safety of Felzartamab Infusions in Adults With Kidney Transpla
 nts Who Have Antibody-Mediated Rejection (AMR)\nEstimated primary completi
 on: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 felzartamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06685757
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602258-665@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT06602258)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Study of E2814 With Concurrent Lecanemab Treatment in Participants With Ea
 rly Alzheimer's Disease\nEstimated primary completion: 3 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-665@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT03887455)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study to Confirm Safety and Efficacy of Lecanemab in Participants With Ear
 ly Alzheimer's Disease\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03887455
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602193-1609@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BIIB122 / DNL151 (LRRK2 inhibitor): Phase 2 readout est. (NCT066021
 93)
DESCRIPTION:BIIB122 / DNL151 (LRRK2 inhibitor)\, phase 2\, Parkinson's Dise
 ase.\nStudy: Safety and Pharmacodynamic Effects of BIIB122 in Participants
  With LRRK2-Associated Parkinson's Disease (LRRK2-PD)\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/biib122-dnl151-lrrk2-inhibitor#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06602193
URL:https://assetmemo.bio/drug/biib122-dnl151-lrrk2-inhibitor#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06872125-9001@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Zorevunersen: Phase 3 readout est. (NCT06872125)
DESCRIPTION:Zorevunersen\, phase 3\, Dravet Syndrome.\nStudy: A Double-blin
 d Study Evaluating the Efficacy\, Safety\, and Tolerability of Zorevunerse
 n in Patients With Dravet Syndrome\nEstimated primary completion: March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/zorevunersen#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06872125
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03958877-6981@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Plegridy (peginterferon beta-1a): Phase 3 readout est. (NCT03958877
 )
DESCRIPTION:Plegridy (peginterferon beta-1a)\, phase 3\, Multiple Sclerosis
 .\nStudy: A Study to Evaluate the Safety\, Tolerability\, and Efficacy of 
 BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatmen
 t of Relapsing-Remitting Multiple Sclerosis\nEstimated primary completion:
  20 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peginte
 rferon-beta-1a#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03958877
URL:https://assetmemo.bio/drug/peginterferon-beta-1a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935357-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06935357)
DESCRIPTION:Felzartamab\, phase 3\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab Infusions on Adults With Immunoglobuli
 n A Nephropathy (IgAN)\nEstimated primary completion: 31 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06935357
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05809531-907@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT05809531)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: An Open-Label\, Non
 randomized\, Multicenter Extension Study to Evaluate the Long-term Safety 
 and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Im
 mune-Complex Membranoproliferative Glomerulonephritis\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05809531
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594798-4915@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04594798)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Polatuzumab V
 edotin\, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL\nE
 stimated primary completion: 31 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04594798
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-10800@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Qalsody (Tofersen): Phase 3 readout est. (NCT04856982)
DESCRIPTION:Qalsody (Tofersen)\, phase 3\, Amyotrophic Lateral Sclerosis.\n
 Study: Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and Abo
 ut Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develop
 ed ALS Symptoms\nEstimated primary completion: 7 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04856982
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067790-10799@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Spinraza (Nusinersen): Phase 3 readout est. (NCT05067790)
DESCRIPTION:Spinraza (Nusinersen)\, phase 3\, Spinal Muscular Atrophy.\nStu
 dy: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB0
 58) Given as Injections to Participants With Spinal Muscular Atrophy (SMA)
  Who Were Previously Treated With Risdiplam (ASCEND)\nEstimated primary co
 mpletion: 24 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nusinersen#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05067790
URL:https://assetmemo.bio/drug/nusinersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722546-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07722546)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About The Effec
 ts of Felzartamab on Thyroid Function and Its Safety in Adults With Graves
 ' Disease Ages 18 to 75 Years Old\nEstimated primary completion: 31 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/felzartamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07722
 546
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219043-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280210
DTEND;VALUE=DATE:20280211
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07219043)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About the Effec
 ts of Felzartamab Infusions in Adults With Kidney Transplants Who Have Lat
 e Isolated Microvascular Inflammation\nEstimated primary completion: 10 Fe
 bruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felzarta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07219043
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889362-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07889362)
DESCRIPTION:Felzartamab\, phase 2\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab on the Kidneys of Adults With Immunogl
 obulin A Nephropathy (IgAN)\nEstimated primary completion: 13 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07889362
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939802-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07939802)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About the Effec
 ts of Felzartamab on Daily Living Activities and Its Safety in Adults With
  Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old\nEstimated pr
 imary completion: 19 September 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/felzartamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07939802
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901936-907@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Empaveli (Pegcetacoplan): Phase 2 readout est. (NCT04901936)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 2\, Paroxysmal Nocturnal Hemog
 lobinuria.\nStudy: A Study of Pegcetacoplan in Pediatric Patients With Par
 oxysmal Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacop
 lan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04901936
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468659-665@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT04468659)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: AH
 EAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With 
 Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevate
 d Amyloid and Also in Participants With Early Preclinical Alzheimer's Dise
 ase and Intermediate Amyloid\nEstimated primary completion: 21 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04468659
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04740476-9001@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zorevunersen: Phase 2 readout est. (NCT04740476)
DESCRIPTION:Zorevunersen\, phase 2\, Dravet Syndrome.\nStudy: An Open-Label
  Extension Study of STK-001 for Patients With Dravet Syndrome\nEstimated p
 rimary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zorevunersen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04740476
URL:https://assetmemo.bio/drug/zorevunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06044337-5645@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:Litifilimab: Phase 3 readout est. (NCT06044337)
DESCRIPTION:Litifilimab\, phase 3.\nStudy: A Long-Term Extension Study to L
 earn More About the Safety of Litifilimab (BIIB059) Injections and Whether
  They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous
  Lupus Erythematosus\nEstimated primary completion: 26 June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/litifilimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06044337
URL:https://assetmemo.bio/drug/litifilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-4915@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Evaluate Gl
 ofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and 
 Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgki
 n Lymphoma\nEstimated primary completion: 30 November 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962800-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300128
DTEND;VALUE=DATE:20300129
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06962800)
DESCRIPTION:Felzartamab\, phase 3\, Primary Membranous Nephropathy.\nStudy:
  A Study to Learn More About the Effects and Safety of Felzartamab Infusio
 ns in Adults With Primary Membranous Nephropathy (PMN)\nEstimated primary 
 completion: 28 January 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/felzartamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06962800
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898774-907@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT07898774)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: A Study to Assess t
 he Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3
 G or Primary IC-MPGN in Kidney Transplant Recipients\nEstimated primary co
 mpletion: 17 January 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07898774
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444489-3402@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Felzartamab: Phase 3 readout est. (NCT07444489)
DESCRIPTION:Felzartamab\, phase 3.\nStudy: A Study to Learn More About the 
 Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidne
 y Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular 
 Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)\nEstimated primary completion
 : 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 elzartamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07444489
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05352919-5645@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20320503
DTEND;VALUE=DATE:20320504
SUMMARY:Litifilimab: Phase 3 readout est. (NCT05352919)
DESCRIPTION:Litifilimab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) I
 njections and it's Effects on Symptoms in Adults With Systemic Lupus Eryth
 ematosus (SLE)\nEstimated primary completion: 3 May 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/litifilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05352919
URL:https://assetmemo.bio/drug/litifilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-6976@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:Vumerity (Diroximel fumarate): Phase 3 readout est. (NCT07483632)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 3\, Multiple Sclerosis.\n
 Study: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and D
 imethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Particip
 ants With Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary c
 ompletion: 28 July 2034. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/diroximel-fumarate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07483632
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
